These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.
And…dodgy chinese vaccinations
Report has nothing to do with SARS so it might be a big leap to think China went with a SARS vaccine becuase CCP is a caring open and transparent government as we all know…
With the highest frequency of ACE2 receptors, itll be interesting to see if they start dropping like flies.
Japan is on Chinas doorstep and seem to be holding up so far.
Time will tell.
The Canada link
The SARS Accelerated Vaccine Initiative (SAVI), an international consortium led by the BC centre, is now conducting animal trials of 3 potential vaccines.
China hopes to start its own clinical trials of an indigenously developed whole killed vaccine in January, but Brunham says that shouldn’t preclude trials of the Canadian–developed vaccine.
With SARS most likely to resurface in China, where it originated, it makes sense to conduct clinical trials there, Brunham says. “It would be helpful to Chinese authorities to demonstrate within Chinese populations that the vaccine is safe and would generate the right kind of immune responses.”
Canadian government scientist at the National Microbiology Lab in Winnipeg made at least five trips to China in 2017-18, including one to train scientists and technicians at China’s newly certified Level 4 lab, which does research with the most deadly pathogens, according to travel documents obtained by CBC News.
Funding vaccines for emerging infectious diseases
Gary Wong & Xiangguo Qiu
Pages 1760-1762 | Received 01 Nov 2017, Accepted 24 Nov 2017, Accepted author version posted online: 01 Dec 2017, Published online: 16 Jan 2018
Notable is the lack Hib, ORV, PCV, influenza and HPV vaccines in China’s EPI system – vaccines that are recommended by WHO for all countries’ national immunization programs but are available only as private-sector vaccines in China.
Three vaccines (JEV-L made by Chengdu Institute of Biological Products; InfV, made by Hualan Biological; and inactivated hepatitis A vaccine, made by Sinovac Biotech Co. Ltd.) have been prequalified by WHO, [1, 16] enabling procurement by UNICEF and Gavi for use in other countries